Time to Buy This Embattled Drug Stock?

The following video is from today's MarketFoolery podcast, in which host Chris Hill, along with Charly Travers, Jason Moser, and Joe Magyer, discuss the latest business news. Shares of Elan, Pfizer, and Johnson & Johnson all fell today after the experimental treatment for Alzheimer's disease the three companies were working together on failed its first large clinical trial. While the bigger companies fell only slightly, shares of Elan finished the day down nearly 15%. In this segment, the guys analyze the opportunity Alzheimer's disease presents for companies in the biotechnology and pharmaceutical industries. They also share why, despite the hit its stock took today, Elan is still a company investors should keep their eyes on.

For investors seeking dividend-paying stocks trading at bargain-basement prices, just check out The Motley Fool's free report "2 Dirt Cheap Stocks With HUGE Dividends." You can get analysis of a market leader in payment systems and a high-yielding energy company by accessing this report. It won't be available forever, so simply click here -- it's free.

The article Time to Buy This Embattled Drug Stock? originally appeared on Fool.com.

Chris Hillowns shares of Johnson & Johnson and Pfizer. The Motley Fool owns shares of Johnson & Johnson.Motley Fool newsletter serviceshave recommended buying shares of Johnson & Johnson and Pfizer and creating a diagonal call position in Johnson & Johnson. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. Try any of our Foolish newsletter servicesfree for 30 days. The Motley Fool has adisclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.